Brant Firestone Selected Research

SHP099

1/2016

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brant Firestone Research Topics

Disease

8	Neoplasms (Cancer) 11/2020 - 09/2010
1	Breast Neoplasms (Breast Cancer) 12/2018
1	Glioblastoma (Glioblastoma Multiforme) 07/2018
1	Glioma (Gliomas) 07/2018
1	Leukemia 11/2016

Drug/Important Bio-Agent (IBA)

2	Oncogene Proteins (Oncogene Protein)IBA 01/2019 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 07/2018 - 11/2016
1	AminesIBA 11/2020
1	Protein Tyrosine PhosphatasesIBA 01/2019
1	Aromatase InhibitorsIBA 12/2018
1	Selective Estrogen Receptor Modulators (SERM)IBA 12/2018
1	Estrogen Receptor alphaIBA 12/2018
1	LSZ102IBA 12/2018
1	Estrogen ReceptorsIBA 12/2018
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 07/2018
1	SHP099IBA 01/2016
1	tyrosine receptor (receptor, tyrosine)IBA 01/2016
1	Immunologic Factors (Immunomodulators)IBA 01/2016
1	Phosphotransferases (Kinase)IBA 01/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	Non-Receptor Type 11 Protein Tyrosine PhosphataseIBA 01/2016
1	Histone Deacetylases (Histone Deacetylase)IBA 07/2011
1	Histone Deacetylase InhibitorsIBA 07/2011
1	Inhibitor of Apoptosis ProteinsIBA 09/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2010

Therapy/Procedure

3	Therapeutics 12/2018 - 09/2010